BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15058772)

  • 1. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
    Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
    J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
    Finotello R; Stefanello D; Zini E; Marconato L
    Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
    Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
    Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide.
    Sorenmo KU; Jeglum KA; Helfand SC
    J Vet Intern Med; 1993; 7(6):370-6. PubMed ID: 8114034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
    Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
    J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
    Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
    J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine hemangiosarcoma treated with standard chemotherapy and minocycline.
    Sorenmo K; Duda L; Barber L; Cronin K; Sammarco C; Usborne A; Goldschmidt M; Shofer F
    J Vet Intern Med; 2000; 14(4):395-8. PubMed ID: 10935889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
    U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
    J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
    Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL
    J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
    Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
    Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
    Matsuyama A; Poirier VJ; Mantovani F; Foster RA; Mutsaers AJ
    J Am Anim Hosp Assoc; 2017; 53(6):304-312. PubMed ID: 28892429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
    Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
    Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma.
    Wiley JL; Rook KA; Clifford CA; Gregor TP; Sorenmo KU
    Vet Comp Oncol; 2010 Sep; 8(3):221-33. PubMed ID: 20691029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs
    Mullin CM; Arkans MA; Sammarco CD; Vail DM; Britton BM; Vickery KR; Risbon RE; Lachowicz J; Burgess KE; Manley CA; Clifford CA
    Vet Comp Oncol; 2016 Dec; 14(4):e171-e183. PubMed ID: 25524594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VAC protocol for treatment of dogs with stage III hemangiosarcoma.
    Alvarez FJ; Hosoya K; Lara-Garcia A; Kisseberth W; Couto G
    J Am Anim Hosp Assoc; 2013; 49(6):370-7. PubMed ID: 24051260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with DAV for advanced-stage hemangiosarcoma in dogs.
    Dervisis NG; Dominguez PA; Newman RG; Cadile CD; Kitchell BE
    J Am Anim Hosp Assoc; 2011; 47(3):170-8. PubMed ID: 21498593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery and doxorubicin in dogs with hemangiosarcoma.
    Ogilvie GK; Powers BE; Mallinckrodt CH; Withrow SJ
    J Vet Intern Med; 1996; 10(6):379-84. PubMed ID: 8947871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
    Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
    J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.
    Borgatti A; Fieberg A; Winter AL; Stuebner K; Taras E; Todhunter D; Masyr A; Rendhal A; Vallera DA; Koopmeiners JS; Modiano JF
    Vet Comp Oncol; 2020 Dec; 18(4):664-674. PubMed ID: 32187827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.